Combined Pituitary Hormone Deficiencies Market Report 2024

The combined pituitary hormone deficiencies market size has grown strongly in recent years. It will grow from $1.83 billion in 2023 to $1.95 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period can be attributed to several factors, including increased awareness and diagnosis of the condition, a growing aging population, advancements in targeted therapies, and a higher prevalence of cancer and genetic predispositions.

The combined pituitary hormone deficiencies market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth during the forecast period can be attributed to several factors, including rising rates of chronic health conditions, long-term health impacts, increasing genetic research, improvements in healthcare access, and advancements in health infrastructure. Major trends expected during this period include advanced imaging techniques, genetic testing and precision medicine, biomarkers and molecular diagnostics, as well as the integration of artificial intelligence (AI) and machine learning.

The rising incidence of pituitary tumors is expected to drive growth in the combined pituitary hormone deficiencies market. Pituitary tumors are abnormal growths in the pituitary gland, which regulates hormone production in the brain. Exposure to endocrine-disrupting chemicals found in some plastics, pesticides, and personal care products may contribute to hormonal imbalances and abnormalities in the pituitary gland. These tumors can lead to combined pituitary hormone deficiency by disrupting the gland's ability to produce multiple hormones, causing hormonal imbalances. For example, the American Cancer Society, a US-based non-profit organization, reported in October 2022 that over 10,000 pituitary tumors are diagnosed annually in the United States. Thus, the increasing incidence of pituitary tumors is contributing to the rise in combined pituitary hormone deficiencies.

Leading companies in the combined pituitary hormone deficiencies market are developing advanced treatments such as body-identical hormone therapy (HRT) to improve patient compliance, reduce the frequency of administration, and enhance overall treatment effectiveness. Body-identical HRT uses hormones that are identical to those naturally produced by the body to address hormone deficiencies or imbalances. For instance, in June 2023, Theramex, a UK-based specialty pharmaceutical company, introduced Bijuva, a combined hormone therapy for post-menopausal women. This product combines 1 mg of estradiol and 100 mg of progesterone in a single daily capsule, replicating the body’s natural hormones. It is designed for women with an intact uterus who are at least a year post-menopause, providing a body-identical solution for estrogen deficiency symptoms.

In December 2023, Xponential Fitness Inc., a US-based health and wellness company, acquired Lindora for an undisclosed amount. This acquisition aims to meet the growing consumer demand for comprehensive health solutions and leverage the expanding market for wellness services worldwide. Lindora Clinic, a US-based facility, specializes in metabolic health and offers a range of services, including weight loss programs, hormone replacement therapy, and IV hydration.

Major companies operating in the combined pituitary hormone deficiencies market are Pfizer Inc., Merck & Co Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Ipsen Group, Cipla Inc., Ferring Pharmaceuticals, Lupin Limited, LEO Pharma A/S, Glenmark Pharmaceuticals Limited, AnkeBio Co Ltd., Aeterna Zentaris Inc., Anhui Anke Biotechnology Co Ltd., GeneScience Pharmaceuticals Co Ltd., Strongbridge Biopharma plc.

North America was the largest region in the combined pituitary hormone deficiencies market in 2023. The regions covered in the combined pituitary hormone deficiencies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the combined pituitary hormone deficiencies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Combined pituitary hormone deficiencies are a rare condition marked by the inadequate production of two or more hormones by the pituitary gland. This disorder usually arises from developmental or functional abnormalities, leading to symptoms that can include growth and developmental delays, infertility, and metabolic issues. Treatment typically involves lifelong hormone replacement therapy to manage symptoms and enhance quality of life.

The inheritance patterns for combined pituitary hormone deficiencies include autosomal dominant, autosomal recessive, and X-linked recessive. Autosomal dominant inheritance means that a single copy of a mutated gene from one parent is enough to cause the disorder. Diagnosis often involves blood tests, imaging tests, and other diagnostic methods. Treatment options include hormone replacement therapy, levothyroxine, corticosteroids, and other medications, which are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. End users of these treatments include hospitals, specialty clinics, home care settings, and other healthcare providers.

The combined pituitary hormone deficiencies market research report is one of a series of new reports that provides combined pituitary hormone deficiencies market statistics, including combined pituitary hormone deficiencies industry global market size, regional shares, competitors with a combined pituitary hormone deficiencies market share, detailed combined pituitary hormone deficiencies market segments, market trends and opportunities, and any further data you may need to thrive in the combined pituitary hormone deficiencies industry. This combined pituitary hormone deficiencies market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The combined pituitary hormone deficiencies market includes revenues earned by entities providing services such as diagnosis and monitoring, multidisciplinary care, and nutritional and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. The combined pituitary hormone deficiencies market also consists of sales of growth hormone products, insulin pens, and auto-injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.